Neta Milman1, Jia Zhu2, Christine Johnston3, Anqi Cheng4, Amalia Magaret5, David M Koelle6, Meei-Li Huang7, Lei Jin7, Alexis Klock7, Erik D Layton1, Lawrence Corey8. 1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Laboratory Medicine. 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Medicine. 4. Department of Biostatistics. 5. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Laboratory Medicine Department of Medicine Department of Biostatistics. 6. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Laboratory Medicine Department of Medicine Department of Global Health, University of Washington, Seattle. 7. Department of Laboratory Medicine. 8. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Laboratory Medicine Department of Medicine.
Abstract
BACKGROUND: Herpes simplex virus type 2 (HSV-2) reactivation is accompanied by a sustained influx of CD4(+) and CD8(+) T cells that persist in genital tissue for extended periods. While CD4(+) T cells have long been recognized as being present in herpetic ulcerations, their role in subclinical reactivation and persistence is less well known, especially the role of CD4(+) regulatory T cells (Tregs). METHODS: We characterized the Treg (CD4(+)Foxp3(+)) population during human HSV-2 reactivation in situ in sequential genital skin biopsy specimens obtained from HSV-2-seropositive subjects at the time of lesion onset up to 8 weeks after healing. RESULTS: High numbers of Tregs infiltrated to the site of viral reactivation and persisted in proximity to conventional CD4(+) T cells (Tconvs) and CD8(+) T cells. Treg density peaked during the lesion stage of the reactivation. The number of Tregs from all time points (lesion, healed, 2 weeks after healing, 4 weeks after healing, and 8 weeks after healing) was significantly higher than in control biopsy specimens from unaffected skin. There was a direct correlation between HSV-2 titer and Treg density. CONCLUSIONS: The association of a high Treg to Tconv ratio with high viral shedding suggests that the balance between regulatory and effector T cells influences human HSV-2 disease.
BACKGROUND:Herpes simplex virus type 2 (HSV-2) reactivation is accompanied by a sustained influx of CD4(+) and CD8(+) T cells that persist in genital tissue for extended periods. While CD4(+) T cells have long been recognized as being present in herpetic ulcerations, their role in subclinical reactivation and persistence is less well known, especially the role of CD4(+) regulatory T cells (Tregs). METHODS: We characterized the Treg (CD4(+)Foxp3(+)) population during humanHSV-2 reactivation in situ in sequential genital skin biopsy specimens obtained from HSV-2-seropositive subjects at the time of lesion onset up to 8 weeks after healing. RESULTS: High numbers of Tregs infiltrated to the site of viral reactivation and persisted in proximity to conventional CD4(+) T cells (Tconvs) and CD8(+) T cells. Treg density peaked during the lesion stage of the reactivation. The number of Tregs from all time points (lesion, healed, 2 weeks after healing, 4 weeks after healing, and 8 weeks after healing) was significantly higher than in control biopsy specimens from unaffected skin. There was a direct correlation between HSV-2 titer and Treg density. CONCLUSIONS: The association of a high Treg to Tconv ratio with high viral shedding suggests that the balance between regulatory and effector T cells influences humanHSV-2 disease.
Authors: Christine Johnston; Jia Zhu; Lichen Jing; Kerry J Laing; Christopher M McClurkan; Alexis Klock; Kurt Diem; Lei Jin; Jeffrey Stanaway; Elizabeth Tronstein; William W Kwok; Meei-Li Huang; Stacy Selke; Youyi Fong; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey Journal: J Virol Date: 2014-02-19 Impact factor: 5.103
Authors: L A Koutsky; C E Stevens; K K Holmes; R L Ashley; N B Kiviat; C W Critchlow; L Corey Journal: N Engl J Med Date: 1992-06-04 Impact factor: 91.245
Authors: Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Jia Zhu; David M Koelle; Jianhong Cao; Julio Vazquez; Meei Li Huang; Florian Hladik; Anna Wald; Lawrence Corey Journal: J Exp Med Date: 2007-02-26 Impact factor: 14.307
Authors: Jia Zhu; Florian Hladik; Amanda Woodward; Alexis Klock; Tao Peng; Christine Johnston; Michael Remington; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey Journal: Nat Med Date: 2009-08-02 Impact factor: 53.440
Authors: Laura E Richert-Spuhler; Laura Pattacini; Margot Plews; Elizabeth Irungu; Timothy R Muwonge; Elly Katabira; Nelly Mugo; Adrienne F A Meyers; Connie Celum; Jared M Baeten; Jairam R Lingappa; Jennifer M Lund Journal: AIDS Date: 2019-11-15 Impact factor: 4.177
Authors: Brianna Traxinger; Sarah C Vick; Amanda Woodward-Davis; Valentin Voillet; Jami R Erickson; Julie Czartoski; Candice Teague; Martin Prlic; Jennifer M Lund Journal: Mucosal Immunol Date: 2022-07-11 Impact factor: 8.701
Authors: Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald Journal: AIDS Date: 2018-11-13 Impact factor: 4.177